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Abstract
Inflammatory bowel diseases (IBD) are chronic and relapsing
inflammatory conditions of the gastrointestinal tract including
Crohn’s disease (CD) and ulcerative colitis (UC). Galectins, defined
by shared consensus amino acid sequence and affinity for
b-galactosides, are critical modulators of the inflammatory
response. However, the relevance of the galectin network in the
pathogenesis of human IBD has not yet been explored. Here, we
analyzed the expression of relevant members of the galectin fam-
ily in intestinal biopsies, and identified their contribution as novel
mucosal markers in IBD. Colonic biopsies were obtained from 59
IBD patients (22 CD and 37 UC), 9 patients with gut rejection after
transplantation, 8 adult celiac patients, and 32 non-IBD donors.
Galectin mRNA expression was analyzed by RT-PCR and qPCR
using specific primers for individual galectins. A linear discrimi-
nant analysis (LDA) was used to analyze galectin expression in
individual intestinal samples. Expression of common mucosal-
associated galectins (Gal-1, 23, 24, 29) is dysregulated in
inflamed tissues of IBD patients compared with noninflamed IBD
or control samples. LDA discriminated between different inflam-
mation grades in active IBD and showed that remission IBD sam-
ples were clusterized with control samples. Galectin profiling
could not distinguish CD and UC. Furthermore, inflamed IBD was
discriminated from inflamed tissue of rejected gut in transplanted
patients and duodenum of celiac patients, which could not be dis-
tinguished from control duodenum samples. The integrative anal-
ysis of galectins discriminated IBD from other intestinal
inflammatory conditions and could be used as potential mucosal
biomarker.VC 2015 BioFactors, 00(00):000–000, 2015
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1. Introduction
Galectins are a family of evolutionarily conserved lectins widely
distributed in the animal kingdom [1]. These lectins are defined by
two common features: a carbohydrate recognition domain com-
posed by a shared consensus amino acid sequence and affinity for
b-galactoside containing glycans. To date, 15 members of the
galectin family have been identified in different mammalian tis-
sues. According to their architecture, galectins have been classi-
fied into prototype (Gal-1, 22, 25, 27, 210, 211, 213, 214, and
215), chimera type (Gal-3), and tandem-repeat type (Gal-4, 26,
28, 29 and 212) [2]. They have been shown to play pivotal roles
as regulators of immune cell homeostasis and inflammation, by
regulating cell survival and signaling, influencing chemotaxis, and
interfering with cytokine secretion [3–5]. Several cell types, includ-
ing epithelial cells, endothelial cells, and mucosal-associated
immune cells are major sources of galectins and key targets of
their biological effects in the intestinal ecosystem [6–11].
Inflammatory bowel diseases (IBD) are chronic disorders of
the gastrointestinal tract of unknown etiology with a typically
relapsing and remitting course. Crohn’s disease (CD) and ulcera-
tive colitis (UC) represent the two main forms of IBD [12]. These
pathologies typically differ in their histology, type of lesion, loca-
tion, and prognosis, and both are characterized by heterogeneous
symptoms indicative of an underlying inflammatory process [13].
Nevertheless, in both cases, immune, environmental, and genetics
factors have been documented as key players that contribute to
persistent inflammation and subsequent mucosal lesions leading
to a mucosal immune dysfunction [14]. Although the etiology of
IBD remains unknown, a growing body of experimental evidence
supports a link between chronic inflammatory disorders and a
failure of the mucosal immune system to restore homeostasis and
restrict the aberrant immune response against the microbiota. In
this scenario, the role of galectins in IBD is not fully understood.
These endogenous lectins are widely expressed by several intesti-
nal cell subsets [7,15,16] and galectin–glycan interactions have
been implicated in the pathogenesis of intestinal inflammation in
murine models of colitis [9,17]. In studies using human intestinal
samples, Gal-3, 24, and 29 have been implicated in the pathoge-
nesis of IBD by modulating the migratory capacity of fibroblasts
and regulating T cell survival [8,18,19]. Given the important roles
of glycan-binding proteins in mucosal-associated compartments,
delineating their expression profile in physiologic and pathologic
settings is relevant for the implementation of potentially novel
diagnostic, prognostic, and therapeutic approaches. Here we pro-
pose an integrated analysis of the expression profile of multiple
galectins involved in intestinal disorders, which discriminates IBD
from noninflamed tissues or from other intestinal inflammatory
conditions, indicating their potential use as novel mucosal
markers for IBD diagnosis andmonitoring.
2. Materials and Methods
This study was approved by the Ethics Committee of the
Udaondo Hospital for Gastroenterology (Buenos Aires, Argen-
tina). In all cases, tissue samples were obtained with the consent
of patients.
2.1. Patients and Sample Collection
Colon biopsies were collected from 25 UC patients and 18 CD
patients with endoscopic features of active disease (clinical
data is shown in Tables T11 and 2) and 22 non-IBD controls (10
women and 12 men, mean age: 47, range: 22–75 years). IBD
patients were diagnosed based on clinical, endoscopic, and
histopathologic findings according to accepted criteria of
Lennard-Jones and Geboes et al. [20,21]. Clinical disease activ-
ity was graded according to the partial Mayo Score for UC
patients [22] and the Hervey–Bradshaw Index (HBI) for CD
patients [21,23]. Total ileocolonoscopy was performed and
four biopsies (two for RNA extraction and two for pathology)
adjacent to each other were taken from the colonic segment
with the most severe activity observed (inflamed IBD samples).
Clinical features of endoscopic active UC patients
(n 5 25)
Characteristics and parameters n Median (range)
Age 43 (18–75)
Sex
Male 11
Female 14
Intestinal location
Proctitis 4
Left-sided colitis 10
Extensive 11
Partial Mayo scorea
Remission (0–1) 5
Mild disease (2–4) 11
Moderate disease (5–6) 3
Severe disease (7–9) 6
IBSEN score
1 8
2 17
Histology
Mild inflammatory infiltrate 12
Marked inflammatory infiltrate 13
aWithout endoscopy.
IBSEN: inflammatory bowel disease in SouthEastern Norway.
TABLE 1
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The endoscopic disease activity in both types of IBD patients
was evaluated according to the Inflammatory Bowel disease in
SouthEastern Norway (IBSEN) study published by Frøslie et al.
[24]. This index is one of the endoscopic activity scales consid-
ered to be used for the European Evidence-Based Consensus
for Endoscopy in IBD [25]. Unlike the Mayo subendoscopic
scoring, Crohn’s Disease Endoscopic Index of Severity (CDEIS),
and Simple Endoscopic Score for Crohn’s Disease (SES-CD),
the IBSEN score has been designed to be utilized for both UC
and CD. This allowed us to draw parallels between patients
with different diagnosis, but with equivalent degree of severity,
condition that we regarded as an advantage for this study. We
considered the score of the colonic segment where biopsies
were obtained. Briefly, the inflammatory status of the mucosa
was scored from 0 to 2 by endoscopic evaluation by the same
observer, a gastroenterologist with experience in endoscopic
diagnosis of IBD: 05normal; 1 light erythema or granularity;
25 granularity, friability, and bleeding, with or without ulcera-
tions. In this study, we considered as inflammation all findings
different to score 0. Therefore, scores of 1 and 2 were consid-
ered as “weak inflammation” and “marked inflammation,”
respectively (the latter includes both moderate and severe
changes). Histological degree of inflammation was assessed by
an expert pathologist, blindly with respect to the endoscopist
grading. The histological severity of mucosal inflammation
was determined according to Saverymuttu et al. [26] with
minor modifications. Briefly, histologic inflammation was clas-
sified as “mild inflammatory infiltrate” and “marked inflam-
matory infiltrate” (the latter includes moderate and severe
inflammation).
Noninflamed samples were taken from noninvolved areas,
with no macroscopic inflammation or history of activity in the
segment, from 13 UC and 13 CD patients. The study also
included 16 IBD patients with quiescent disease, 12 with UC
and 4 with CD (mean age: 52.5, range: 18–80 years). Quiescent
UC and CD patients were in clinical remission and samples
were taken from areas that were previously documented as
inflamed but without current signs of endoscopic activity
(endoscopic score50). Remission was achieved in these
patients with the following treatments: mesalazine (2), mesala-
zine and antibiotics (1), sulfasalazine (3), 6-mercaptopurine
(7), 6-mercaptopurine and thalidomide (1), infliximab (1), and
infliximab and 6-mercaptopurine (1).
Non-IBD control patients were endoscopically examined
because of abdominal pain, constipation, irritable bowel syn-
drome, screening of colorectal cancer, or history of polyp
resection. No signs of macroscopical or histologic features of
IBD inflammation were observed in these patients [27].
In addition, samples from patients that underwent gut
transplantation, and experienced gut rejection were included
(n 5 9). Patients aged 10–47 years received isolated intestinal
transplantation due to short bowel syndrome secondary to
multiple surgical resections as a result of volvulus or traumatic
injuries without chronically intestinal pathology. In all cases,
no postoperative complications upon the intestinal transplanta-
tion were detected and patients were subjected to routine
endoscopic follow-up until diagnosis of acute cellular rejection
according to international criteria [28]. Patients received corti-
coids (methylprednisolone or meprednisone) and tacrolimus
(4), or corticosteroids (methylprednisolone or meprednisone),
tacrolimus and rapamicin or mycophenolate (5) as immuno-
suppressive treatments.
Duodenal biopsies were obtained from adult patients dur-
ing routine procedures to diagnose celiac disease (n 5 8).
Patients aged 20–40 were diagnosed by clinical, serological,
and histological criteria. Control nonceliac patients (n 5 10)
with other gastrointestinal conditions, primarily dyspepsia,
with negative serology for celiac disease and normal duodenal
histology were also analyzed.
2.2. RNA Isolation and Real-Time RT-PCR
Intestinal tissue samples collected by endoscopy were immedi-
ately placed in 0.5 mL RNA later (Ambion, USA) at 4 8C and
stored at 280 8C until processing. Total RNA extraction was
performed by means of total RNA isolation system (Macherey
Nagel, Duren, Germany) following the manufacturer’s instruc-
tions. Random primers and MMLV-reverse transcriptase (Invi-
trogen, Carlsbad, CA, USA) were used for reverse transcription
of isolated RNA. Real-time quantitative PCR (qPCR) for Gal-1,
Gal-3, Gal-4, Gal-9, STAT4, GATA3, and T-bet was performed
using SYBR Green PCR Master Mix (BioRad, Hercules, CA,
USA) in the iCycler thermal cycler (Bio-Rad, Hercules, CA,
USA). The relative expression level of genes was determined
using human b-actin as a normalizer. Primers’ sequence were
as follows: Gal-1 forward: 50-TGAACCTGGGCAAAGACAGC-30;
reverse: 50-TTGGCCTGGTCGAAGGTGAT-30, Gal-3 forward: 50-
GAAGGGAAGAAAGACAGTCG-30; reverse: 50-CAAGTGAGCATCA
TTCACTG-30, Gal-4 forward: 50-CGAGGAGAAGAAGATCA
CCC-30; reverse: 50-CTCTGGAAGGCCGAGAGG-30, Gal-9: forward:
50-CTTTCATCACCACCATTCTG-30, reverse: 50-ATGTGGAACCTCT
GAGCACTG-30, STAT4: forward: 50-GATCTGCAAGACGAATTT
GAC-30; reverse: 50-TGTCACTCTGATCCATTGTC-30; GATA3:
forward: 50-GCTTCACAATATTAACAGACCC-30; reverse: 50-GTT
AAACGAGCTGTTCTTGG-30; T-bet: forward: AGAATGCCGA-
GATTACTCAG: reverse: TACATGGACTCAAAGTTCTCC. b-actin
forward: 50-CCTGGCACCCAGCACAAT-30; reverse: 50-GCCGAT
CCACACGGAGTACT-30.
2.3. Statistical Analysis
Comparison between groups was performed using analysis of var-
iance (ANOVA) and Tukey’s test. P values lower than 0.05 were
considered statistically significant. A normal control range for
each galectin was defined as mRNA levels lying between Q1 2 1.5
3 IQR and Q311.5 3 IQR (Q1: 1st quartile; Q3: 3rd quartile; IQR:
interquartile range, all belonging to the control population).
Linear discriminant analysis (LDA) was used to separate
predefined groups using a linear combination of variables
(gene expression) [29]. Data were plotted in a multidimen-
sional graph in which similar objects lie close to one another
and clusterized. LDA was used to determine whether control
and IBD patients can be discriminated, as well as UC from CD
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patients. In addition, LDA was assessed to discriminate IBD
inflammation, gut transplantation, and celiac patients. Leave-
one-out cross-validation was used to confirm graphical segre-
gation. Each sample was randomly excluded from analysis as
the remaining database was used to generate an algorithm to
predict the excluded sample identity. This procedure was
repeated as many times as samples were in the database,
always excluding a different sample. Finally, we obtained a
percentage of success as cross-validation (CV) % that indicates
how many times samples were recategorized within the previ-
ously defined group.
A receiver operating characteristic (ROC) curve represent-
ing sensitivity (true-positive rate) versus specificity (false-posi-
tive rate) was built. The area under the ROC curve (AUC) is a
diagnostic measure indicating if a variable (mRNA expression
level of galectins or transcription factors, or a linear combina-
tion thereof) can be used to distinguish between two groups
(control vs IBD). An AUC value of 1 corresponds to a system
capable of a perfect discrimination, whereas a value of 0.5
indicates a complete lack of discriminative power.
3. Results
3.1. Galectin Profile is Homogenously Distributed in
Different Sections of the Colon
To investigate the profiles of intestinal galectins in IBD and other
relevant intestinal pathologies, we first analyzed control biopsies
of non-IBD patients corresponding to ascending, transverse,
descending, and sigmoid colon, and rectum for Gal-1, Gal-3, Gal-
4, and Gal-9 mRNA expression (Fig.F1 1A). No statistical differences
were observed between the different intestinal sections, demon-
strating a homogenous and ubiquitous galectin mRNA expression
throughout the colon. This finding led us to analyze biopsies of
colonic mucosa, irrespective of the colonic segment. Interestingly,
we found that Gal-4 was the most highly expressed galectin
within the colon, with mRNA levels comparable to those of
b-actin, followed by Gal-3, Gal-9, and Gal-1, respectively.
3.2. Galectins are Differentially Expressed in the
Inflamed Mucosa of IBD Patients
We next sought to analyze biopsies obtained from colonic
inflamed tissues of both UC and CD patients (Fig. 1B). We
found a significant deregulation of galectin mRNA expression
in severe inflamed tissues compared with biopsies from control
patients. Results showed that noninvolved areas from tissues
corresponding to IBD patients (noninflamed tissues) showed a
similar galectin profile as control samples. Moreover, Gal-1
and Gal-4 were differentially expressed in mild inflamed areas
compared with control samples. Regarding areas with more
prominent inflammatory infiltrates, all galectins analyzed
showed a differential gene expression profile as compared
with control tissues. We found that Gal-1 mRNA considerably
increased, whereas Gal-3, Gal-4, and Gal-9 mRNA substan-
tially dropped in areas with pronounced inflammation. These
results suggest that severe inflammation leads to a significant
deregulated expression of the human galectin network. More-
over, galectin expression showed unsatisfactory AUC when
mild inflamed and control samples were compared (Fig. 1C).
However, we found that all galectins showed a high sensitivity
and specificity for delineating marked inflamed areas of IBD
patients from control samples (AUC>0.8), which was even
more pronounced for Gal-4 (AUC50.99) than for other galec-
tins analyzed (Fig. 1D).
However, analysis of individual galectins in control samples
did not enable us to define a cutoff value of gene expression to
distinguish control vs IBD samples (Fig. 1B). Our results showed
that although individual analysis of gene expression correspond-
ing to these galectins may provide an approximation of the
mucosal status, it can discriminate noninflamed from inflamed
tissues in a restricted percentage of cases (Gal-1 5 40%; Gal-
35 0%; Gal-45 42%; and Gal-95 58%). These results prompted
us to run a multiparametric analysis of galectin gene expression
including all galectins in the same matrix.
3.3. Galectin mRNA Expression Distinguishes Inflamed
IBD Mucosa from Control Tissue and Reflects Disease
Activity
Seeking for an integrated analysis of the galectin signature in
IBD, we clusterized gene expression of galectins under differ-
ent conditions using the LDA. The leave-one-out cross-valida-
tion analysis allowed us to evaluate the performance of the
estimates. The LDA showed no significant differences between
control and noninflamed IBD samples, whereas inflamed IBD
samples could be discriminated (Fig. F22A). Remarkably, also
remission IBD samples were similarly clusterized as control
samples, suggesting that once inflammation is resolved by
treatment, the pattern of galectin expression recapitulates that
found in healthy mucosa. The cross-validation (CV) analysis
rendered the following CV percentages: inflamed IBD, 81.40%
(n 5 43); noninflamed IBD, 23.08% (n 5 26); remission IBD,
25.00% (n 5 16), and control, 31.82% (n 5 22). The leave-one-
out cross-validation analysis classified 35/43 IBD samples as
belonging to the inflamed cluster.
When we investigated the galectin gene expression profile
in samples from tissues with different degree of endoscopic
inflammation, we found that the LDA reflected disease activity
(Fig. 2B). Samples from areas with mild inflammation were dis-
criminated from those with marked inflammation and control
samples. The leave-one-out cross-validation analysis prompted
us to correlate the progression of the disease with the integrated
galectin expression. We found CV values for mild inflamed,
active inflamed, or control samples tissues of 66.67% (n 5 18),
72.00% (n5 25), and 82.82% (n5 22), respectively.
3.4. Galectin mRNA Expression Profile does not
Discriminate between CD and UC
Although the LDA showed a good performance to delineate IBD
from control samples, with an AUC 5 0.97 (Fig. F33A),
CVIBD 5 92% and CVCONTROL 5 82%, it could not discriminate CD
from UC samples (Fig. 3B). The leave-one-out cross-validation
analysis rendered the following percentages: CVCD 5 44.44%
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(n 5 18), CVUC 5 44.00% (n 5 25), and CVCONTROL 5 81.82%
(n5 22). In order to improve disease discrimination analysis, we
next incorporated CD- or UC-associated immune markers (stat-
4, gata-3, and t-bet). The LDA of the immune markers (Fig. 3C)
did not distinguish IBD from control samples (AUC 5 0.72,
CVIBD 5 58%, and CVCONTROL 5 77%). Nevertheless, the addition
of immune markers to galectin expression analysis (Fig. 3D) dis-
criminated control from IBD samples, although CD and UC were
still indiscernible (CVCD 5 31.25%; CVUC 5 40.91%, and
CVCONTROL 5 86.36%). Overall, these findings indicate that
Galectin gene expression profile in human colon samples. (A) Galectin mRNA expression by qPCR in the different sections of
the healthy colon: Ascending (Asc), transverse (Trs), descending (Desc), and sigmoid colon (Re). (B) mRNA levels of individual
galectins in control patients and inflamed tissues of patients with IBD. Receiver operating characteristic (ROC) curve for the
individual galectin gene expression and corresponding area under the curve (AUC) statistics for evaluation of samples with (C)
mild inflammation or (D) active inflammation. Galectin mRNA levels were normalized relative to human b-actin. Samples were
analyzed in duplicate and data are expressed as mean values6 standard error of the mean (SEM). Line indicates the normal
control range (***P < 0.001, **P < 0.01, *P < 0.05).
FIG 1
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analysis of mucosal galectin gene expression mostly contributed
to discriminate between IBD and control samples. Additionally,
our results suggest that these endogenous lectins are equally
deregulated in CD and UC inflamed tissues.
3.5. Galectins can Discriminate Inflamed IBD from
Other Types of Intestinal Inflammatory Responses
To understand whether the aberrant pattern of galectin gene
expression observed in IBD patients is specific of the inflam-
matory processes occurring in UC and CD, we performed the
same analysis in biopsies from patients with other intestinal
inflammatory conditions. We analyzed intestinal biopsies from
small bowel of patients with active celiac disease, patients that
received gut transplantation and underwent rejection, and
healthy control patients. When performing the LDA, we found a
clear discrimination of the inflammatory response between
celiac disease and gut transplant rejection (Fig. F44A). However,
the centroid corresponding to celiac samples was close to con-
trol duodenum samples. In fact, cross-validation analysis
showed that half of the samples from celiac patients were rede-
fined as control samples, while 78% of samples from rejected
gut were gathered as themselves, and distant from normal and
celiac centroids (CVCELIAC 5 50.00%; CVREJECTION 5 77.78%;
CVCONTROL 5 70.00%). These data suggest that the LDA could
not distinguish inflammation in celiac patients from control duo-
denum. On the contrary, inflammation in gut rejection samples
Linear discriminant analysis of galectin gene expression profile in control and IBD colonic samples. (A) Multivariate analysis of
Gal-1, 23, 24, and 29 mRNA expression in inflamed active IBD, noninflamed IBD, remission IBD, and control samples. (B)
Analysis of galectin gene expression in biopsies from patients with different disease activity, and control samples. Right panels
show the centroids corresponding to the analysis of mRNA expression of the four galectins. Samples were analyzed in
duplicate.
FIG 2
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showed a galectin expression pattern discernible from other
samples (Fig. 4A). When gene expression of individual galectins
was compared between control duodenum and inflammation
associated with small bowel rejection, Gal-1 showed the main
difference with a fourfold increased expression in gut rejection
samples. Significant differences were also observed in Gal-3
expression levels (Fig. 4B). However, no differences in individual
galectin gene expression profiles were observed between control
and celiac patients (data not shown).
Finally, we analyzed whether variations in the galectin
expression pattern occurred between distinct inflammatory
disorders. Because celiac disease and gut rejection affect
mainly the small bowel, whereas IBD (CD and UC) affect the
colon, we next compared the galectin expression signature in
small bowel and colon from healthy control individuals. Of
note, we found differential expression of individual galectins in
both tissues examined (Fig. F55A). The four galectins analyzed
were highly expressed in the normal colon as compared with
healthy duodenum, being Gal-4 the most highly expressed
galectin. In addition, Gal-9 displayed the greatest changes in
expression (3.5-fold in colon). The integrated analysis of galec-
tins rendered different clusters of gene expression profile cor-
responding to healthy small bowel and colon (Fig. 5B), and
leave-one-out cross-validation analysis confirmed the graphi-
cal segregation: CVSMALL BOWEL 5 90%; CVCOLON 5 90.91%.
Finally, even though the galectin expression profile of the
duodenum differed from that of the colon, the integrated anal-
ysis showed distant centroids when samples of active IBD
Linear discriminant analysis of galectin gene expression profile and T cell-associated transcription factors in control and IBD
colonic samples. (A) Multivariate analysis of galectin mRNA expression in active IBD and control samples. ROC and AUC statis-
tics for discrimination of IBD and control samples were calculated. (B) Multivariate analysis for discrimination of active CD
from UC. Centroids for inflamed CD and UC vs control patients were plotted using Gal-1, Gal-3, Gal-4, and Gal-9 mRNA expres-
sion. (C) Discriminant analysis of transcription factor (GATA-3, STAT-4, and T-bet) mRNA expressions in active IBD and control
samples. ROC and AUC statistics were calculated. (D) Multivariate analysis and clustering of inflamed CD and UC vs control
samples with centroids were plotted using Gal-1, Gal-3, Gal-4,Gal-9, GATA-3, STAT-4, and T-bet mRNA expression. Samples
were analyzed in duplicate.
FIG 3
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were compared with controls and gut rejection specimens
(CVCONTROL COLON 5 86.66%, CVCONTROL SMALL BOWEL 5 80%,
CVIBD 5 73.68%; CVGUT REJECTION 5 66.67%) (Fig. 5B). Overall,
these findings indicate substantial differences in galectin
expression profiles in IBD (CD and UC) patients as compared
to healthy individuals and patients suffering celiac disease or
gut rejection.
4. Discussion
In the past few years, a number of experimental mouse models
of IBD revealed the critical role of galectins in the resolution of
gut inflammation and attenuation of colitis [7,9,18]. In this
study, we identified a mucosal galectin signature, which could
be potentially used as a mucosal marker for different intestinal
inflammatory conditions, including IBD. We analyzed Gal-1,
Gal-3, Gal-4, and Gal-9 mRNA by qPCR and found that galectin
gene expression can discriminate intestinal inflammation in IBD
from celiac disease patients and patients undergoing rejection
following gut transplantation. Furthermore, active IBD speci-
mens, regardless of whether they were EC or UC, could be dis-
criminated from noninflamed, quiescent IBD mucosa or from
non-IBD control tissues. Noticeably, disease activity was
reflected in the performed linear discriminant analysis. In addi-
tion, analysis of biological specimens from 22 control and 59
IBD patients demonstrated that galectins are homogeneously
expressed throughout the different sections of healthy colon,
with a deregulated expression in inflamed tissues.
Individual and linear discriminant analysis of galectin gene expression in inflamed tissues of celiac patients, patients with gut
rejection and control patients. (A) LDA and centroids plotted using galectin gene expression profiles of samples from control
duodenum, celiac, and gut rejection in transplanted patients. (B) mRNA expression corresponding to galectins in normal duo-
denum and gut rejection. Samples were analyzed in duplicate and data are expressed as mean values6 standard error of the
mean (SEM) (***P < 0.001, **P < 0.01).
FIG 4
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Galectins analyzed in this study were selected based on their
critical involvement in gut mucosa homeostasis [19,30–32]. It has
been reported that Gal-1 exerts a protective and immunomodula-
tory activity during TNBS-induced colitis [30], which might be
mediated through the induction of IL-10 secretion and modula-
tion of T cell survival [4,33]. On the other hand, Muller et al.
showed that Gal-3 promotes death of activated T cells [7], while
Lippert et al. showed the ability of this chimera-type galectin to
control migration of lamina propria fibroblasts, thus promoting
stricture and fistula formation in Gal-3-depressed mucosa
[15,18]. Moreover, Nishida et al. demonstrated that i.v. adminis-
tration of high doses of Gal-4 leads to delayed recovery of DSS-
induced colitis [34]. Further, Hokama et al. demonstrated
increased synthesis of Gal-4 by intestinal epithelial cells and
proinflammatory activity. This lectin interacts with colonic lam-
ina propria CD41 T cells, forming surface lattices and stimulating
IL-6 production and PKC h activation, with the subsequent delay
recovery from acute intestinal injury [34,35]. On the other hand,
Linear discriminant analysis of galectin gene expression profiles of control duodenum, control colon, inflamed tissues of active
IBD, and gut rejection. (A) mRNA expression corresponding to galectins in normal duodenum and colon. (B) Multivariate analy-
sis of galectin mRNA expression in samples of control duodenum and colon. Centroids were plotted based on Gal-1, Gal-3,
Gal-4, and Gal-9 mRNA expression. (C) Multivariate analysis for discrimination of samples from active IBD, control colonic tis-
sue, and samples from rejected gut. Centroids were plotted according to the mRNA expression corresponding to the four
galectins examined. Samples were analyzed in duplicate and data are expressed as mean values6 standard error of the mean
(***P < 0.001, **P < 0.01, *P < 0.05).
FIG 5
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Paclik et al. documented that low continuous doses of Gal-4
reduced the disease activity index in a colitis model by induction
of mucosal T cell apoptosis as well as suppression of proinflam-
matory cytokines [8]. These apparent discrepancies could be rec-
onciled, at least in part by the different concentrations of this
tandem-repeat galectin as well as the roles of endogenous versus
exogenous Gal-4 and the impact of local versus systemic delivery
of this lectin in experimental IBD. Finally, Gal-9 has been shown
to promote apoptosis of Th1 cells through interaction with T-cell
immunoglobulin and mucin domain-3 (TIM-3) [36]. It has been
reported that expression of TIM-3 and Gal-9 is decreased in CD
and UC patients inducing an imbalance of Th17 and T regulatory
(Treg) cells [36,37]. In summary, experimental IBD models show
that Gal-1,23,24, and29 play key roles in the intestinal homeo-
stasis and may contribute to the pathogenesis of IBD through dif-
ferent, although partially overlapping mechanisms.
Here we found that all members of the galectin family
analyzed were homogeneously expressed through different
sections of the large bowel. Although individual galectin gene
expression profiles were differentially induced in active IBD,
we could not identify a potential biological indicator of disease
activity with enough predictive value to be clinically used as a
mucosal biomarker. Nevertheless, the multivariate and inte-
grated analysis of gene expression of these four galectins pre-
dicted in 82% of the active IBD samples (mild and actively
inflamed) that they were indeed obtained from IBD patients. Of
note, this analysis reflected the disease activity in inflamed tis-
sues, while healing in UC and CD patients could not be distin-
guished from control or non-inflamed mucosa. However, active
CD and UC could not be discriminated by our multivariate and
integrated analysis, thus emphasizing the fact that galectins
are similarly deregulated in both inflammatory conditions. On
the contrary, when galectins were analyzed in inflamed tissues
of rejected grafts from patients that underwent gut transplan-
tation, we found that the LDA distinguished active IBD from
rejected inflamed mucosa and control mucosa. Interestingly,
when other inflammatory conditions such as celiac disease
were analyzed, a completely different scenario was revealed.
Duodenal samples from control adults and patients with active
celiac disease could not be discriminated; however, they were
clearly different from duodenal samples from patients under-
going gut rejection. Thus, integrated analysis of galectin gene
expression reflects the differential regulation of these endoge-
nous glycan-binding proteins in each inflammatory condition.
In this regard, one might hypothesize that variations in galec-
tin expression could reflect differences in the underlying mech-
anisms that govern intestinal inflammatory disorders and
might correlate with the natural history of the disease in each
individual patient.
Although this integrated algorithm could efficiently manage
to discriminate patients with IBD diagnosis, CD could not be dis-
tinguished from UC even when immune markers were differen-
tially expressed (at the mRNA level) in both inflammatory disor-
ders (e.g., gata-3, a Th2 transcription factor associated with
UC, and stat-4 and t-bet, Th1 transcription factors associated
with CD) were included in the multivariate analysis [38,39]. In f
act, using the ROC curve, we observed a better performance of
the galectin gene expression profile (AUC 5 0.97), when com-
pared to analysis of the expression of transcription factors
(AUC 5 0.72) for discriminating IBD and control samples. Fur-
thermore, LDA showed close centroids corresponding to control
samples, nonactive and quiescent IBD distinguishable from
active IBD. These findings suggest that inflammation leads to
Clinical features of endoscopic active CD patients
(n 5 18)
Characteristics and parameters n Median (range)
Age 43 (20–73)
Sex
Male 6
Female 14
Age of diagnostic
<30 6
30–40 6
>40
Intestinal Location
8
Colon only 18
Small bowel and colon
disease behavior
2
Non stricturing or fistulizing 11/5p
Stricturing 2/1p
Fistulizing 0/1p
HBI
Remission (<4) 5
Mild disease (5–7) 11
Moderate to severe
disease (8–12)
4
IBSEN score
1 6
2 14
Histology
Mild inflammatory infiltrate 11
Marked inflammatory infiltrate 9
p: with perianal compromise.
HBI: Harvey–Bradshaw index.
IBSEN: inflammatory bowel disease in SouthEastern Norway.
TABLE 2
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deregulation in galectin gene expression profiles, likely aimed
at limiting the inflammatory process and restoring mucosal
homeostasis. In this regard, by studying intestinal necrosis in
neonates diagnosed with necrotizing enterocolitis, Sylvester
et al. found that the multivariate and integrated analysis of clin-
ical parameters in combination with urine peptide biomarkers,
improved the prognostic accuracy of disease progression in
comparison with clinical or analytical parameters individually
analyzed [29].
In this work, we provided evidence that the galectin gene
expression profile is significantly deregulated in active
inflamed mucosa from IBD (both CD and UC) patients and
reflects disease activity. Since Gal-1 is a well-known anti-
inflammatory factor, and it is upregulated in the active
inflamed mucosa, we suggest that it may play a resolving role
in IBD by controlling the survival of activated proinflammatory
Th1 and Th17 cells and triggering regulatory circuits mediated
by tolerogenic dendritic cells, FoxP31 Treg cells and M2-type
macrophages [3,5,40]. Similar speculations could be made
with regards to Gal-3 and Gal-4, which have been shown to
modulate T cell activation, proinflammatory cytokine synthesis
and T cell apoptosis [7,8]. Further studies are needed to
address the specific role of endogenous galectins in the patho-
genesis of CD and UC.
Although serum and fecal markers are increasingly used
[41–43], colonoscopy and mucosal sampling are routine proce-
dures for diagnosis and monitoring the disease in IBD patients
and remains the only reliable procedure to assess mucosal
inflammation. In fact, frequent lack of correlation is observed
between clinical, endoscopic, and histological findings [44]. As
shown in Tables 1 andT2 2, according to the partial Mayo score
without endoscopy and the HBI, 20% (5/25) of UC patients and
25% (4/18) of CD patients showed endoscopic signs of inflam-
mation but no clinical manifestations.
Different criteria about disease remission impact in the
management of the patient and results of clinical trials. Cur-
rently, there is no international consensus that defines endo-
scopic mucosal healing [45], and histological assessment is still
controversial and need further examination [27]. Therefore,
both mucosa with no abnormalities and mucosa with mild
inflammation might be considered as “healing.” Given that
changes in mRNA expression are fast events, galectin gene
expression in intestinal samples may constitute potential
mucosal biomarkers to rapidly assess the evolution and sever-
ity of inflammation during active disease, to predict possible
relapses, or to monitor the inflammation status of the mucosa
once pharmacological treatment has been initiated.
In conclusion, in this study, we identified the relevance of
mucosal galectins as potential markers of the severity of
mucosal inflammation in IBD patients. Quantification of Gal-1,
Gal-3, Gal-4, and Gal-9 mRNA in intestinal biopsies and the
ensemble multivariate analysis provide an improved tool to
distinguish active IBD from control patients, quiescent IBD,
and other intestinal inflammatory disorders and to assess dis-
ease activity in IBD patients. Further studies will be necessary
to determine whether galectin gene expression may reflects
changes occurring during the natural course of IBD or follow-
ing different treatments in clinical trials.
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